

05-11-07

Express Mail Label No.: EV942366625US

Date of Deposit: May 9, 2007

Attorney Docket No. 24852-502 NATL



18w

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS :	Bacopoulos, et al.	CONFIRMATION NUMBER :	5497
SERIAL NUMBER :	10/567,953	EXAMINER :	Not yet assigned
I.A. FILING DATE :	August 12, 2004	INT'L APPLICATION NO :	PCT/US04/26161
PRIORITY DATE :	August 29, 2003	ART UNIT :	Not yet assigned
FOR :	Combination Methods of Treating Cancer		

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages) in duplicate;
2. Modified Form PTO-1449 (3 pages); in duplicate;
3. Cited References A11-A20; B3-B14; C9-73; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (212) 935-3000.

The Commissioner is authorized to charge any fees that may be due or to credit any overpayment of same to the undersigned's account, Deposit Account No. **50-0311**, Customer Number: **35437**, Reference Number: **24852-502 NATL**.

Respectfully submitted,

Dated: May 9, 2007

Michelle A. Iwamoto

Ivor R. Elrifi, Reg. No. 39,529
Michelle A. Iwamoto, Reg. No. 55,296
Attorneys/Agents for Applicants
c/o MINTZ, LEVIN, *et al.*
666 Third Avenue-24th Floor
New York, New York 10017
Telephone: (212) 983-3000
Telefax: (212) 983-3115



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS :	Bacopoulos, et al.	CONFIRMATION NUMBER :	5497
SERIAL NUMBER :	10/567,953	EXAMINER :	Not yet assigned
I.A. FILING DATE :	August 12, 2004	INT'L APPLICATION NO :	PCT/US04/26161
PRIORITY DATE :	August 29, 2003	ART UNIT :	Not yet assigned
FOR :	Combination Methods of Treating Cancer		

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. In accordance with MPEP §609(III)(A)(2), copies of the cited U.S. patents and U.S. publications are not required.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-identified application. Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims. It is also respectfully requested that the Examiner initial, sign and date, and return a copy of the signed modified Form PTO-1449 with the next U.S. PTO communication, to evidence that the cited information has been fully considered by the U.S. Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

The order of presentation of the references should not be construed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 24852-502 NATL, Customer No. 35437.

Respectfully submitted,

Dated: May 9, 2007

Michelle A. Iwamoto

Ivor R. Elrifi, Reg. No. 39,529
Michelle A. Iwamoto, Reg. No. 55,296
Attorneys/Agents for Applicants
c/o MINTZ, LEVIN, *et al.*
666 Third Avenue-24th Floor
New York, New York 10017
Telephone: (212) 983-3000
Telefax: (212) 983-3115

Please type a plus sign (+) in this box

PTO/SB (12-97)
 OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Mailed Form 1449/PTO		Application Number	10/567,953
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		International Application Number	PCT/US04/26161
		I.A. Filing Date	August 12, 2004
		Priority Date	August 29, 2003
		First Named Inventor	Bacopoulos, et al.
		Group Art Unit / Conf. No.:	Not Yet Assigned / 5497
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	24852-502 NATL

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date
A11	4,522,811	06/11/85	Eppstein, et al.	514	2	07/08/82	
A12	5,369,108	11/29/94	Breslow, et al.	514	266	10/04/91	
A13	5,055,608	10/08/91	Marks, et al.	560	169	06/30/89	
A14	5,175,191	12/29/92	Marks, et al.	514	575	05/14/90	
A15	5,608,108	03/04/97	Marks, et al.	562	621	04/17/95	
A16	5,700,811	12/23/97	Breslow, et al.	514	314	05/19/94	
A17	5,773,474	06/30/98	Breslow, et al.	514	616	06/07/95	
A18	5,932,616	08/03/99	Breslow, et al.	514	532	04/04/94	
A19	6,087,367	07/11/00	Breslow, et al.	514	266	05/18/99	
A20	6,511,990	01/28/03	Breslow, et al.	514	314	08/24/00	

FOREIGN PATENT DOCUMENTS						
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	English Yes	No
B3	WO	97/11366	Merck & Co., Inc.	March 27, 1997	X	
B4	WO	98/40080	Beacon Laboratories, L.L.C.	September 17, 1998	X	
B5	WO	98/48825	The Salk Institute for Biological Studies	November 5, 1998	X	
B6	WO	00/08048	Fujisawa Pharmaceutical Co., Ltd.	February 17, 2000	X	
B7	WO	00/21979	Fujisawa Pharmaceutical Co., Ltd.	April 20, 2000	X	
B8	WO	0071703	Methylgene Inc.	November 30, 2000	X	
B9	WO	01/18171	Sloan-Kettering Institute for Cancer Research and the Trustees of Columbia University	March 15, 2001	X	
B10	WO	01/38322	Methylgene Inc.	May 31, 2001	X	
B11	WO	01/70675	Methylgene Inc.	September 27, 2001	X	
B12	WO	02/46144	F. Hoffmann-La Roche AG	June 13, 2002	X	
B13	WO	02/22577	Novartis	March 21, 2002	X	
B14	WO	02/30879	Prolifix Limited	April 18, 2002	X	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
C9		Abe, E., et al., Proc. Natl. Acad. Sci. (USA) 78: 4990-4994 (1981)
C10		Andrews et al., International J. Parasitology 30:761-768 (2000)
C11		Archer, S. et al., PNAS 95:6791-96 (1998)
C12		Awada A., et al. Eur J. Cancer 38, 773-778 (2002)
C13		Black and Livingston, Drugs 39: 489-501 (Part I) (1990)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C14	Black and Livingston, Drugs 39: 652-673 (Part II) (1990)
	C15	Breitman, T. R., et al., Proc. Natl. Acad. Sci. USA 77: 2936-2940 (1980)
	C16	Brosch et al., Plant Cell 7, 1941-1950 (1995)
	C17	Butler, L.M. et al., Cancer Res. 60:5165-5170 (2000)
	C18	Chen and Grem, Curr. Opin. Oncol. 4: 1089-1098 (1992)
	C19	Cohen, L.A. et al., Anticancer Research 19:4999-5006 (1999)
	C20	Cousens et al., J. Biol. Chem. 254,1716-1723 (1979)
	C21	Curtin M., Expert Opin. Ther. Patents, 12(9): 1375-1384 (2002)
	C22	Darkin-Rattray et al., Proc. Natl. Acad. Sci. USA 93,13143-13147 (1996)
	C23	Dressel, U. et al., Anticancer Research 20(2A):1017-22 (2000)
	C24	Ebert, P. S., et al. Cancer Res. 36: 1809-1813 (1976)
	C25	Finnin, M.S., et al., Nature 401:188-193 (1999)
	C26	Frey et al, Bioorganic & Med. Chem. Lett., 12, 3443-3447 (2002)
	C27	Friend, C., et al., Proc. Natl. Acad. Sci., U. S., 68:378-382 (1971)
	C28	Furamai R. et al., PNAS USA 98 (1), 87-92 (2001)
	C29	Grunstein, M., Nature, 389: 349-52 (1997)
	C30	Guan et al., Cancer Research, 60,749-755 (2000)
	C31	Hardman W.E., et al. Br J Cancer 81, 440-448 (1999)
	C32	Hayashi, M., et al., Gann 70: 235-238 (1979)
	C33	Huberman, E. et al., Proc. Natl. Acad. Sci. (USA) 76: 1293-1297 (1979)
	C34	Kijima et al., J Biol. Chem. 268,22429-22435 (1993)
	C35	Kim et al., Oncogene, 18: 2461-2470 (1999)
	C36	Koghe et al., Biochem. Pharmacol. 56: 1359-1364 (1998)
	C37	Komatsu, Y., et al., Cancer Res. 61(11), 4459-4466 (2001)
	C38	Kwon et al., PNAS 95: 3356-3361 (1998)
	C39	Lea et al., Anticancer Research, 15, 879-873 (1995)
	C40	Lee, B.I. et al., Cancer Res. 61(3), 931-934
	C41	Lin, R.J. et al., Nature 391:811-14 (1998)
	C42	Lotem, J. et al., Proc. Natl. Acad. Sci. (USA) 76: 5158-516) (1979)
	C43	Lotem, J., et al., Int. J. Cancer 15: 731-740 (1975)
	C44	Marks et al., Cancer Res. 47:659-666 (1987)
	C45	Marks, P.A. et al., J. Natl. Cancer Inst., 92:1210-1215 (2000)
	C46	McBain et al., Biochem. Pharm. 53: 1357-1368 (1997)
	C47	Metcalf, D., et al., Science, 229: 16-22 (1985)
	C48	Morin, M. J., et al., Cancer Res. 44: 2807-2812 (1984)
	C49	Nakajima et al., Ex. Cell Res. 241,126-133 (1998)
	C50	Olsson, I. L., et al., Cancer Res. 42: 3924-3927 (1982)
	C51	Qiu et al., Mol. Biol. Cell 11, 2069-2083 (2000)
	C52	Reuben, R. C., et al., Proc. Natl. Acad. Sci. (USA) 73: 862-866 (1976)
	C53	Richon et al., Proc. Natl. Acad. Sci. USA, 93:5705-5708 (1996)
	C54	Richon, V. M. et al., Proc. Natl. Acad. Sci., USA, 95:3003-3007 (1998)
	C55	Sachs, L., Nature (Lond.) 274: 535 (1978)
	C56	Saito et al., Proc. Natl. Acad. Sci. USA 96, 4592-4597 (1999)
	C57	Scher, W. et al., Exp. Hematol. 11: 490-498 (1983)
	C58	Scher, W., et al., Biochem. & Biophys. Res. Comm. 109: 348-354) (1982)
	C59	Schwartz, E. L., et al., Cancer Res. 42: 2651-2655 (1982)
	C60	Schwartz, E. L., et al., Cancer Res. 43: 2725-2730 (1983)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C61	Schwartz, E. L., et al., Proc. Am. Assoc. Cancer Res. 24: 18 (1983)
	C62	Sporn, M. B., et al., Ed. 2, (J. B. Lippincott, Philadelphia), 49 (1985)
	C63	Su et al., Cancer Research, 60: 3137-3142 (2000)
	C64	Sugano, H., et al., Bibl. Hematol. 39: 943-954 (1973)
	C65	Suzuki, T., et al., J. Med. Chem. 42(15), 3001-3003 (1999)
	C66	Takenaga, K., et al., Cancer Res. 40: 914-919 (1980)
	C67	Tanaka, M., et al., Proc. Natl. Acad. Sci. (USA) 72: 1003-1006 (1975)
	C68	Terada, M., et al., Proc. Natl. Acad. Sci. (USA) 75: 2795-2799 (1978)
	C69	Van Lint, C. et al., Gene Expression 5:245-53 (1996)
	C70	Wang et al., Cancer Research, 59, 2766-2799 (1999)
	C71	Yoshida, M. et al., J. Biol. Chem., 265:17174-17179, (1990)
	C72	Yoshida, M., et al., Bioassays 17, 423-430 (1995)

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered
--------------------	--	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.